Challenges in obesity management

Southern Medical Journal

Volumn 91, Issue 8, 1998, Pages 710-720

  Carlos Poston II, Walker S ^a   Foreyt, John P ^a   Borrell, Leo ^a   Haddock, C Keith ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]PROPYL]BENZOIC ACID METHYL ESTER HYDROGEN MALEATE; ACETYLSALICYLIC ACID; AMFEPRAMONE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ENDORPHIN; CAFFEINE; CHOLECYSTOKININ; CHOLECYSTOKININ DERIVATIVE; DEXFENFLURAMINE; EPHEDRINE; FENFLURAMINE; FLUOXETINE; INSULIN; LEPTIN; LIPID; MAZINDOL; NEUROPEPTIDE Y; PHENTERMINE; PROTEIN; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BEHAVIOR THERAPY; BODY MASS; CALORIC INTAKE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIET; DRUG EFFICACY; DRUG SAFETY; ENERGY EXPENDITURE; FOOD AND DRUG ADMINISTRATION; GENE; HEALTH CARE COST; HEALTH INSURANCE; HEART PALPITATION; HUMAN; INSOMNIA; LIFESTYLE; NONHUMAN; NUTRITION; OBESITY; PHYSICAL ACTIVITY; POLICY; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; RISK FACTOR; VALVULAR HEART DISEASE;

EID: 3543012538     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199808000-00002     Document Type: Review

References (110)

1. Kuczmarski RJ, Flegal KM, Campbell SM, et al: Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960-1991. JAMA 1994; 272:205-211
2. Andres R, Muller DC, Sorkin JD: Long-term effects of change in body weight on all-cause mortality: a review. Ann Intern Med 1993; 119:737-743
3. Pi-Sunyer FX: Medical hazards of obesity. Ann Intern Med 1993; 119:655-660
4. Solomon CG, Willett WC, Manson JE: Body weight and mortality. Obesity: New Directions in Assessment and Management. Van Itallie TB, Simopoulos AP (eds). Philadelphia, Charles Press, 1995, pp 1-11
5. Troiano RP, Frongillo EA Jr, Sobal J, et al: The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies. Int J Obes Relat Metab Disord 1996; 20:63-75
6. Allison DB, Gallagherr D, Heo M, et al: Body mass index and all-cause mortality among people age 70 and over: the longitudinal study of aging. Int J Obes Relat Metab Disord 1997; 21:424-431
7. Black DR, Sciacca JP, Coster DC: Extremes in body mass index: probability of healthcare expenditures. Prev Med 1994; 23:385-393
8. Gortmaker SL, Must A, Perrin JM, et al: Social and economic consequences of overweight in adolescence and young adulthood. N Engl J Med 1993; 329:1008-1012
9. Hutton J: The economics of treating obesity. PharmacoEconomics 1994; 5(suppl 1):66-72
10. Martin LF, Hunter SM, Lauve RM, et al: Severe obesity: expensive to society, frustrating to treat, but important to confront. South Med J 1995; 88:895-902
11. Wolf AM, Colditz GA: The cost of obesity: the U.S. perspective. PharmacoEconomics 1994; 5(suppl 1):34-37
12. Wolf AM, Colditz GA: Social and economic effects of body weight in the United States. Am J Clin Nutr 1996; 63(suppl):466S-469S
13. Sjöström L, Narbro, K, Sjöström D: Costs and benefits when treating obesity. Int J Obes Relat Metab Disord 1995; 19(suppl 6):S9-S12
14. Dattilo AM, Kris-Etherton PM: Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992; 56:320-328
15. Kanders BS, Blackburn GL: Reducing primary risk factors by therapeutic weight loss. Treatment of the Seriously Obese Patient. Wadden TA, Van Itallie TB (eds). New York, Guilford Press, 1992, pp 213-230
16. Williamson DF, Pamuk ER, Thun M, et al: Prospective study of intentional weight loss and mortality in never-smoking overweight U.S. white women aged 40-64 years. Am J Epidemiol 1995; 141:1128-1141
17. Perri MG, Fuller PR: Success and failure in the treatment of obesity: where do we go from here? Med Exerc Nutr Health 1995; 4:255-272
18. Foreyt JP, Goodrick GK: Promoting long-term weight maintenance. Obesity: Pathophysiology, Psychology, and Treatment. Blackburn GL, Kanders BS (eds). New York, Chapman & Hall, 1994, pp 300-311
19. Safer DJ: Diet, behavior modification, and exercise: a review of obesity treatments from a long-term perspective. South Med J 1991; 84:1470-1474
20. Pate RR, Pratt M, Blair SN, et al: Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995; 273:402-407
21. US Department of Health and Human Services: Physical Activity and Health: A Report of the Surgeon General. Atlanta, Ga, US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996
22. Foreyt JP, Goodrick GK: Attributes of successful approaches to weight loss and control. Appl Prev Psychol 1994; 3:209-215
23. Grilo CM: The role of physical activity in weight loss and weight loss management. Med Exerc Nutr Health 1995; 4:60-76
24. Barlow CE, Kohl I, Gibbons LW, et al: Physical fitness, mortality, and obesity. Int J Obes Relat Metab Disord 1995; 19(suppl 4):S41-S44
25. Juneau M, Rogers F, de Santos V, et al: Effectiveness of self-monitored home-based, moderate-intensity exercise training in middle-aged men and women. Am J Cardiol 1987; 60:66-70
26. King AC, Taylor CB, Haskell WL, et al: Strategies for increasing early adherence to and long-term maintenance of home-based exercise training in healthy middle-aged men and women. Am J Cardiol 1988; 61:628-632
27. King AC, Haskell WL, Taylor CB, et al: Group-vs home-based exercise training in healthy older men and women: a community-based trial. JAMA 1991; 266:1535-1542
28. King AC, Haskell WL, Young DR, et al: Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years. Circulation 1995; 91:2596-2604
29. Perri MG, Martin AD, Leermakers EA, et al: Effects of group-versus home-based exercise in the treatment of obesity. J Consult Clin Psychol 1997; 65:278-285
30. Bray GA: Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993; 119:707-713
31. Stunkard AJ: Current views on obesity. Am J Med 1997; 100:230-236
32. AACE/ACE Obesity Task Force: AACE/ACE position statement on the prevention, diagnosis, and treatment of obesity. Endocr Pract 1997; 3:162-208
33. NAASO: Guidelines for the approval and use of drugs to treat obesity. a position paper of the North American Association for the Study of Obesity. Obes Res 1995; 3:473-178
34. Institute of Medicine: Weighing the Options: Criteria for Evaluating Weight-Management Programs. Washington, DC, National Academy Press, 1995
35. National Task Force on the Prevention and Treatment of Obesity: Long-term pharmacotherapy in the management of obesity. JAMA 1996; 276:1907-1915
36. Bray GA, Ryan DH, Gordon D, et al: Double-blind, randomized, placebo-controlled trial of sibutramine. Obes Res 1996; 4:263-270
37. Ryan DH, Kaiser P, Bray GA: Sibutramine: a novel new agent for obesity treatment. Obes Res 1995; 3(suppl 4):553S-559S
38. Stock MJ: Sibutramine-a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord 1997; 21(suppl 1):S25-S29
39. Lean MEJ: Sibutramine-a review of clinical efficacy. Int J Obes Relat Metab Disord 1997; 21(suppl 1 ):S30-S36
40. Rosenbaum M, Leibel RL, Hirsch J: Obesity. N Engl J Med 1997; 337:396-407
41. Pellymounter MA, Cullen MJ, Baker MB, et al: Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269:540-543
42. Wolff GL: Obesity as a pleiotropic effect of gene action. J Nutr 1997; 127:1897S-1901S
43. Zhang Y, Proenca R, Maffei M, et al: Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372:425-432
44. Isse N, Ogawa Y, Tamura N, et al: Structural organization and chromosomal assignment of the human obese gene. J Biol Chem 1995; 270:27728-27733
45. Maffei M, Halaas J, Ravussin E, et al: Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1:1155-1161
46. Considine RV, Sinha MK, Heiman ML, et al: Serum immunoreactive-leptin concentration in normal-weight and obese humans. N Engl J Med 1996; 334:292-325
47. Bray MS, Boerwinkle E, Hanis CL: OB gene not linked to human obesity in Mexican American affected sib pairs from Starr County, Texas. Hum Genet 1996; 98:590-595
48. Carlsson B, Lindell K, Gabrielsson B, et al: Obese (ob) gene defects are rare in human obesity. Obes Res 1997; 5:30-35
49. Considine RV, Caro JF: Leptin genes, concepts, and clinical perspective. Horm Res 1996; 46:249-256
50. Ravussin E, Pratley RE, Maffei M, et al: Relatively low plasma leptin concentrations precede weight gain in Pima Indians. Nat Med 1997; 3:238-240
51. Ericsson M, Poston WSC, Foreyt JP: Common biological pathways in eating disorders and obesity. Addict Behav 1996; 21:733-743
52. Drewnowski A; Metabolic determinants of binge eating. Addict Behav 1995; 20:733-745
53. Drewnowski A, Krahn DD, Demitrack MA, et al: Naloxone, an opiate blocker, reduces the consumption of sweet, high-fat foods in obese and lean female binge eaters. Am J Clin Nutr 1995; 61:1206-1212
54. Bray GA: Nutrient intake is modulated by peripheral peptide administration. Obes Res 1995; 3(suppl 4):569S-572S
55. Leibowitz SF: Brain peptides and obesity: pharmacological treatment. Obes Res 1995; 3(suppl 4):573S-589S
56. Guerciolini R: Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21(suppl 3):S12-S23
57. Drent ML, van der Veen EA: Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes Relat Metab Disord 1993; 17:241-244
58. Drent ML, Larsson I, William-Olsson T, et al: Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord 1995; 19:221-226
59. Drent ML, van der Veen EA: First clinical studies with orlistat: a short review. Obes Res 1995; 3(suppl 4):623S-625S
60. James WPT, Avenell A, Broom J, et al: A one-year trial to assess the value of orlistat in the management of obesity, Int J Obes Relat Metab Disord 1997; 21(suppl 3):S24-S30
61. Connacher AA, Bennet, WM, Jung RT: Clinical studies with beta-adrenoreceptor agonist BRL 26830A. Am J Clin Nutr 1992; 55(suppl 1):258S-261S
62. Connacher AA, Jung RT, Mitchell PE: Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical beta adrenoreceptor agonist. BMJ 1988; 296:1217-1220
63. Chapman BJ, Farquahar DL, Galloway SM, et al: The effects of a new beta-adrenoreceptor agonist BRL 26830A in refractory obesity. Int J Obes Relat Metab Disord 1988; 12:119-123
64. Weintraub M, Sundaresan PR, Madan M, et al: Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 1992; 51:586-594
65. Weintraub M, Sundaresan PR, Madan M, et al: Long-term weight control study II (weeks 34 to 104): an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther 1992; 51:595-601
66. Weintraub M, Sundaresan PR, Schuster B, et al: Long-term weight control study III (weeks 104 to 156): an open-label study of dose adjustment of fenfluramine and phentermine. Clin Pharmacol Ther 1992; 51:602-607
67. Weintraub M: Long-term weight control study: conclusions. Clin Pharmacol Ther 1992; 51:642-646
68. Atkinson RL, Blank RC, Loper JF, et al: Combined drug treatment of obesity. Obes Res 1995; 3(suppl 4):497S-500S
69. Craighead LW, Stunkard AJ, O'Brien M: Behavior therapy and pharmacotherapy for obesity. Arch Gen Psychiatry 1981; 38:763-768
70. Stunkard AJ, Craighead LW, O'Brien R: Controlled trial of behaviour therapy, pharmacotherapy, and their combination in the treatment of obesity. Lancet 1980; 2:1045-1047
71. Craighead LW: Sequencing of behavior therapy and pharmacotherapy for obesity. J Consult Clin Psychol 1984; 52:190-199
72. Davis R, Faulds D: Dexfenfluramine. an updated review of its therapeutic use in management of obesity. Drugs 1996; 52:696-724
73. Guy-Grand B, Apfelbaum M, Crepaldi G, et al: International trial of long-term dexfenfluramine in obesity. Lancet 1989; 2:1142-1144
74. Guy-Grand B: INDEX (international dexfenfluramine study) as a model for long-term pharmacotherapy of obesity in the 1990s. Int J Obes Relat Metab Disord 1992; 16(suppl 3):S5-S14
75. Guy-Grand B: Clinical studies with dexfenfluramine: from past to future. Obes Res 1995; 3(suppl 4):491S-496S
76. Marks SJ, Moore NR, Clark ML, et al: Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Obes Res 1996; 4:1-7
77. O'Connor HT, Richman RM, Steinbeck KS, et al: Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. Int J Obes Relat Metab Disord 1995; 19:181-189
78. Pfohl M, Luft D, Bloomberg I, et al: Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. Int J Obes Relat Metab Disord 1994; 18:391-395
79. Guy-Grand B, Apfelbaum M, Crepaldi G, et al: Effect of withdrawal of dexfenfluramine on body weight and food intake after one year's administration. Int J Obes Relat Metab Disord 1990; 14(suppl 2):48
80. Pedrinola F, Sztejnsznajd C, Lima N, et al: The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial. Obes Res 1996; 4:549-554
81. Goldstein DJ, Rampey AH, Enas GG, et al: Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 1994; 18:129-135
82. Goldstein DJ, Rampey AH, Roback PJ, et al: Efficacy and safety of long-term fluoxetine treatment of obesity-maximizing success. Obes Res 1995; 3(suppl 4):481S-490S
83. Sayler ME, Goldstein DJ, Roback PJ, et al: Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data. Int J Obes Relat Metab Disord 1994; 18:742-751
84. Marcus MD, Wing RR, Ewing L, et al: A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and nonbinge-eaters. Am J Psychiatry 1990; 147:876-881
85. Goldstein DJ, Roback PJ, Holman SL, et al: Individualizing pharmacological therapy for weight reduction: the Lovan example. Obesity: New Directions in Assessment and Management. Van Itallie TB, Simopoulos AP (eds). Philadelphia, Charles Press, 1995, pp 234-240
86. Wadden TA, Bartlett SJ, Foster GD, et al: Sertraline and relapse prevention training following treatment by very-low-calorie-diet: a controlled clinical trial. Obes Res 1995; 3:549-558
87. Astrup A, Breum L, Toubro S, et al: The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. a double blind trial. Int J Obes Relat Metab Disord 1992; 16:269-277
88. Daly PA, Krieger DR, Dulloo AG, et al: Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int J Obes Relat Metab Disord 1993; 17(suppl 1):S73-S78
89. Toubro S, Astrup AV, Breum I., et al: Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture. Int J Obes Relat Metab Disord 1993; 17(suppl 1):S69-S72
90. Anonymous: Adverse events associated with ephedrine-containing products-Texas, December 1993-September 1995. MMWR 1996; 45:689-693
91. Connolly HM, Crary JL, McGoon MD, et al: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337:581-588
92. Abenhaim L, Moride Y, Brenot F, et al: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. JAMA 1996; 335:609-616
93. Food and Drug Administration (FDA): FDA Analysis of Cardiac Valvular Dysfunction With Use of Appetite Suppressants (http://www.fda.gov/cder/news/slides/index.htm, 9/1/97), 1997
94. Centers for Disease Control (CDC): Cardiac valvulopathy associated with fenfluramine or dexfenfluramine: US Department of Health and Human Services Interim Public Health Recommendations, November 1997. MMWR 1997; 46:1061-1066
95. Burke LE, Dunbar-Jacobs J: Adherence to medication, diet, and activity recommendations: from assessment to maintenance. J Cardiovasc Nurs 1995; 9:62-79
96. Foreyt JP, Poston WSC: Building better compliance: factors and methods common to achieving healthy lifestyle. Drugs Affecting Lipid Metabolism: Risk Factors and Future Directions. Gotto AM, Paoletti R, Smith LC, et al (eds). Dordrecht, Netherlands, Kluwer Academic Publishers, 1996, pp 489-496
97. Kirschenbaum DS, Fitzgibbon ML: Controversy about the treatment of obesity: criticisms or challenges? Behav Ther 1995; 26:43-68
98. Foster GD, Wadden TA, Vogt RA, et al: What is reasonable weight loss? patient expectations and evaluations of obesity treatment outcomes, J Consult Clin Psychol 1997; 65:79-85
99. Wadden TA, Berkowitz RI, Vogt RA, et al: Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a primary care approach. Obes Res 1997; 5:218-226
100. Battle EK, Brownell KD: Confronting a rising tide of eating disorders and obesity: treatment vs prevention and policy. Addict Behav 1996; 21:755-765
101. James WPT: A public health approach to the problem of obesity. Int J Obes Relat Metab Disord 1995; 19(suppl 3):S37-S45
102. Jeffery RW: Public health approaches to the management of obesity. Eating Disorders and Obesity. Brownell KD, Fairburn CG (eds). New York, Guilford Press, 1995, pp 558-563
103. Foreyt JP, Goodrick GK: The ultimate triumph of obesity. Lancet 1995; 346:134-135
104. Foreyt JP, Poston WSC, Goodrick GK: Future directions in obesity and eating disorders. Addict Behav 1996; 21:767-778
105. Wise PJ: Clinical experience with a new dosage form of phentermine hydrochloride. Obes Bariatr Med 1975; 4:102-105
106. Munro JF, MacCuish AC, Wilson EM, et al: Comparison of continuous and intermittent anorectic therapy in obesity. BMJ 1968; 1:352-354
107. Enzi G, Baritussio A, Marchiori E, et al: Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity. J Int Med Res 1976; 4:305-318
108. Delfelice EA, Chaykin LB, Cohen A: Double-blind clinical evaluation of mazindol, dextroamphetamine, and placebo in treatment of exogenous obesity. Curr Ther Res Clin Exp 1973; 15:358-366
109. Noble RE: A controlled study of a weight reduction regimen. Curr Ther Res Clin Exp 1971; 13:685-691
110. Nolan GR: Use of an anorexic drug in a total weight reduction program in private practice. Curr Ther Res Clin Exp 1975; 18:332-337